Contesting claims on the safety and acceptability of anti-fertifity vaccines

References

• A.P. Hardon. The needs of women versus the interests of family planning personnel, policy-makers and researchers: conflicting views on safety and acceptability of contraceptives. Social Science and Medicine. 35(6): 1992; 753–766. This paper describes the diverse acceptability and safety issues that emerged but not how women's health advocates disagree among themselves about safety issues.
   Web of Science ®Google Scholar
• WHO/HRP/ ITT/91, Creating Common Ground: Women's Perspectives on the Selection and Introduction of Fertility Regulating Technologies. 1991; WHO: Geneva.
   Google Scholar
• Declaration, International Symposium on Contraceptive Research and Development for the Year 2000 and Beyond, Mexico City 8–10 March 1993
   Google Scholar
• From a Medline search using the keywords fertility, hCG and vaccine.
   Google Scholar
• J. Schrijvers. Dialectics of the dialogical ideal: studying down, studying sideways and studying up. L. Nencel, P. Pels. Constructing Knowledge: Authority and Critique in Social Science. 1991; Sage: London.
   Google Scholar
• W.E. Jones. Immunological Fertility Regulation. 1982; Blackwell Science: Oxford.
   Google Scholar
• J. Barzelatto. Welcoming address. G.L. Ada, P.D. Griffin. Vaccines for Fertility Regulation: The Assessment of Their Safety and Efficacy. 1991; Cambridge University Press: Cambridge.
   Google Scholar
• Research in Huinan Reproduction. Biennial Report 1988–1989. 1990; WHO: Geneva, 27.
   Google Scholar
• J.P. Hearn. Immunization of pregnancy. Proceedings ofthe Royal Society London. 195: 1976; 149–160.
   Google Scholar
• WHO Task Force on Immunological Methods for Fertility Regulation. Evaluating the safety and efficacy of placental antigen vaccines for fertility regulation. Clinical Exp. Immunology. 33: 1978; 360–375. The Task Force on Immunological Methods for Fertility Regulation first met in 1973 with the aim of developing immunological methods of contraception further. The WHO Expanded Programme of Research, Development, and Research Training in Human Reproduction was set up in 1971 and itself set up a number of interdisciplinary task forces consisting of scientists and clinicians to collaborate on specific, research-oriented goals. See also Griffin PD, 1991. WHO Task Force on Vaccines for Fertility Regulation: its formation, objectives and research activities. Human Reproduction. 6(1):166-72.
   Web of Science ®Google Scholar
• H.A. Nash. Observations on the antigenicity and clinical effects of a candidate anti-pregnancy vaccine. Beta-subunit of human chorionic gonadotropin linked to tetanus toxoid. Fertility and Sterility. 34: 1980; 328–335.
   PubMed Web of Science ®Google Scholar
• S.M. Shahani. Clinical and immunological response to Pr-B-hCG TT vaccine. Contraception. 25: 1982; 421–434.
   PubMed Web of Science ®Google Scholar
• G.P. Talwar. Phase I clinical trials with three formulations of antihuman chorionic gonadotropin vaccine. Contraception. 41(3): 1990; 301–316.
   Web of Science ®Google Scholar
• W.R. Jones. Phase I clinical trial of a World Health Organization bird control vaccine. Lancet. 11: 1988; 1295–1298. June.
   Google Scholar
• G.P. Talwar. Anti-fertility vaccines. Vaccine. 7(2): 1989; 97–101.
   Web of Science ®Google Scholar
• See. P.D. Griffin, W.R. Jones. The preliminary clinical evaluation of the safety and efficacy of fertility regulating vaccine. Statistics in Medicine. 10(2): 1991; 178.
   Web of Science ®Google Scholar
• S.K. Gupta. Relevance of immunocontraceptive vaccines for population control. Hormonal immune contraception. Archivum Immunologiae et Therpiae Experimentalis. 38(1–2): 1990; 47.
   Web of Science ®Google Scholar
• J.F. Marshall. Acceptability of fertility regulating methods: designing technology to fit people. Preventive Medicine. 6: 1977; 65–73.
   PubMed Web of Science ®Google Scholar
• G.P. Talwar. An improved immunogen for anti-human chorionic gonadotropin vaccine eliciting antibodies reactive with a conformation native to the hormone without cross-reaction with human follicle stimulating hormone and human thyroid stimulating hormone. Journal of Reproductive Immunology. 14(3): 1988; 210.
   Web of Science ®Google Scholar
• N.A. Mitchison. Gonadotropin vaccines. Current Opinion in Immunology. 2: 1990; 726.
   Web of Science ®Google Scholar
• I interviewed Dr Talwar in August 1996, when he had already retired as director of the NII in New Delhi. Dr Griffin was interviewed in December 1996, during a visit to WHO with two social scientists from Delhi who are doing research on vaccines. See Viswanath K, and Kirbat P, 1997. Genealogy of a Controversy: Development of an Anti-fertility Vaccine. Working Paper No 7. Social Science and Immunization Country Study: India. Centre for Development Economics, Delhi.
   Google Scholar
• G.L. Ada, P.D. Griffin. Vaccines for Fertility Regulation: The Assessment of Their Safety and Efficacy. 1991; Cambridge University Press: Cambridge.
   Google Scholar
• A.P. Harden. An analysis of research on new contraceptive hCG vaccines. WGNRR Newsletter. 1989. April–June[pp15.
   Google Scholar
• P.D. Griffin. Letters on contraceptive vaccine research. WGNRR Newsletter. 32: 1990; 6–7.
   Google Scholar
• J. Richter. Research on antifertility vaccines: priority or problem. WGNRR Newsletter. 39: 1992; 13–18.
   Google Scholar
• A.F. Schrater. Contraceptive vaccines: promises and problems. H. Bequaert Holmes. Issues in Reproductive Technology: An Anthology. 1992; Garland: New York.
   Google Scholar
• Fertility regulating vaccines: report of a meeting between women's health advocates and scientists to review the current status of the development of fertility regulating vaccines, Geneva, Switzerland 17–18 August 1992, WHO/HRP/WHO/ 93.1. 1993. Geneva.
   Google Scholar
• In preparation for the meeting Richter wrote an extensive review of anti-fertility vaccines. J. Richter. Vaccination Against Pregnancy: Miracle or Menace. 1996; Zed Books: London.
   Google Scholar
• Call for a Stop of Research on Antifertility ‘Vaccines’. 1993; WGNRR: Amsterdam.
   Google Scholar
• J. Yanco. Resistance on the rise. Stop Anti-Fertility ‘Vaccines’. Stop anti-fertility ‘vaccines’! International campaign against population control and abusive, hazardous contraceptives. 1996; WGNRR: Amsterdam.
   Google Scholar
• -Benagiano G, Director, Special Programme of Research, Development and Research Training in Human Reproduction, letter dated 21 January 1994; -Gabelnick HL, Director, CONRAD, letter dated 2 March 1 994; -Catley-Carlson M, President, Population Council, letter dated 28 June 1994, (with a request for wide distribution of the letter). All letters were directed to B Stemerding, responding to the ‘Call for a Stop’ campaign.
   Google Scholar
• T.K.S. Ravindran. Contraceptive safety and effectiveness: re-evaluating women's needs and professiona criteria: Introduction. Reproductive Health Matters. 3: 1994; 6–12. (May).
   Google Scholar
• P.D. Griffin. Anti-fertility vaccines current status and implications for family planning programmes. Reproductive Health Matters. 3: 1994; 108–113. (May).
   Google Scholar
• See also. D. Shervington. Questioning the wisdom in changing a part of the whole. Reproductive Health Matters. 4: 1994; 108. (Nov).
   Google Scholar
• R. Macklin. Combatting the potential for abuse. Reproductive Health Matters. 4: 1994; 112.
   Google Scholar
• A.F. Schrater. The pros anc cons: guarded optimism. Reproductive Health Matters. 4: 1994; 110.
   Google Scholar
• M. Berer. Open letter to WGNRR. WGNR Newsletter. 48: 1994; 14–15. (Oct–Dec).
   Google Scholar
• G.P. Talwar. A birth control vaccine is on the horizon for family planning. Annals of Medicine. 25: 1993; 207–212. The antibody titre mentioned is 50ng/ml.
   PubMed Web of Science ®Google Scholar
• G.P. Talwar. A vaccine that prevents pregnancy in women. Proceedings of the National Academy of Science USA. 91: 1994; 8532–8536. (18).
   Google Scholar
• Annual Technical Report 1994. WHO/HRP/ATP/94/95. 1995; WHO: Geneva.
   Google Scholar
• Technology development and assessment: products under development. 1995; WHO Special Programme on Research, Development, and Research Training in Human Reproduction. WHO: Geneva.
   Google Scholar
• Interview with Rosemary Thau, Population Council, March 1993.
   Google Scholar
• IDRC position statement on contraceptive vaccine research. 1995; IDRC: Ottawa.
   Google Scholar
• Bezanson KA, 1997. Letter dated 24 January 1997 to Karen Seabrooke, International Campaign against Population Control and Abusive Hazardous Contraceptives, Canada.
   Google Scholar
• K.S. Jayaraman. India downgrades family planning research. Nature Medicine. 1(5): 1997; 478.
   Web of Science ®Google Scholar
• Paintal D, cited in Viswanath K and Kirbat P,1997. op cit [21], p16.
   Google Scholar
• The role of the Programme in technology development and assessment. A discussion paper. October 1995; UNDP/UNFPA/World Bank/ WHO Special Programme of Research, Development and Research Training in Human Reproduction. WHO: Geneva.
   Google Scholar
• Beyond Acceptability: Users' Perspectives on Contraception. Ravindran TKS, Berer M. and Cottingham J. (eds). Reproductive Health Matters/WHO, London.
   Google Scholar
• R. Snow. Attributes of contraceptive technology: women's preferences in seven countries. T.K.S. Ravindram, M. Berer, J. Cottingham. Beyond Acceptibility: User's Perspectives on Contraception. 1997; 36–48.
   Google Scholar
• Report of the first meeting of the HRP Gender Advisory Panel, Geneva, 12–14 February 1996, 1996; UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction.
   Google Scholar
• Personal communication Jane Cottingham, Technical Officer: Women's Perspectives and Gender Issues, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training, Geneva, October 1997.
   Google Scholar
• B. Stemerding. Letter to all people involved in the campaign. Amsterdam: WGNRR. 1996; WGNRR: Amsterdamd. January 24. (Quote has been modified based on comments by Griffin on the wording cited by Stemerding.).
   Google Scholar
• There was also controversy I did not deal with in this paper, between pro-life groups and public health administrators on the alleged contamination of tetanus toxoid vaccine with antihCG. See Tan ML, 1995. All in the name of life. Reproductive Health Matters. 6(Nov):29–31.
   Google Scholar
• A. Hardon. Women's views and experiences of hormonal contraceptives: what we know and what we need to find out. Report of the first meeting of the HRP Gender Advisory Panel, Geneva, 12–14 February 1996, 1994; UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. 68–78.
   Google Scholar
• This point was made by one of the Indian doctors involved in the clinical trials in an interview with Kalpana Viswanath and Preeti Kirbat, see [46].
   Google Scholar